Three different brain tumours evolving from a common origin

Oncogenesis

Volumn 2, Issue , 2013, Pages

  Forshew, T ^a   Lewis, P ^b   Waldman, A ^b   Peterson, D ^b   Glaser, M ^b   Brock, C ^b   Sheer, D ^a   Mulholland, P J ^c  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

Genetics; Glioblastoma; Heterogeneity; Personalised medicine; Tumour

Indexed keywords

DEXAMETHASONE; PLATELET DERIVED GROWTH FACTOR A; TEMOZOLOMIDE;

ADJUVANT CHEMOTHERAPY; ADULT; ARM WEAKNESS; ARTICLE; ASTROCYTOMA; BASAL GANGLION; CASE REPORT; CHEMORADIOTHERAPY; CHROMOSOME 2; CHROMOSOME 5; CHROMOSOME 7; COORDINATION DISORDER; DISEASE COURSE; DYSPHAGIA; FRONTAL CORTEX; GENE AMPLIFICATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC HETEROGENEITY; GLIOBLASTOMA; GLIOSARCOMA; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MISSENSE MUTATION; MULTIPLE CYCLE TREATMENT; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE MYC; PONS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; STEREOTACTIC BIOPSY; TREATMENT FAILURE;

EID: 84880568455     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2013.1     Document Type: Article

References (31)

1. DeAngelis LM. Brain tumors. N Engl J Med. 2001; 344: 114-123.
2. NICE. Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer). Technology Appraisal Guidance No23 2007.
3. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455: 1061-1068.
4. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321: 1807-1812.
5. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360: 765-773.
6. Wick W, Puduvalli VK, Chamberlain MC, van den Bent MJ, Carpentier AF, Cher LM et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 2010; 28: 1168-1174.
7. Wick W, Weller M, van den Bent M, Stupp R. Bevacizumab and recurrent malignant gliomas: a European perspective. J Clin Oncol 2010; 28: e188-e189.
8. Grossman SA, Ye X, Piantadosi S, Desideri S, Nabors LB, Rosenfeld M et al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res 2010; 16: 2443-2449.
9. Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, Cenci T et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010; 468: 824-828.
10. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-892.
11. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
12. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004; 64: 6892-6899.
13. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.
14. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005; 353: 2012-2024.
15. Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009; 461: 809-813.
16. Pillay V, Allaf L, Wilding AL, Donoghue JF, Court NW, Greenall SA et al. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases. Neoplasia 2009; 11: 448-458.
17. Wager M, Menei P, Guilhot J, Levillain P, Michalak S, Bataille B et al. Prognostic molecular markers with no impact on decision-making: the paradox of gliomas based on a prospective study. Br J Cancer 2008; 98: 1830-1838.
18. Mulholland PJ, Thirlwell C, Brock CS, Newlands ES. Emerging targeted treatments for malignant glioma. Expert Opin Emerg Drugs 2005; 10: 845-854.
19. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007; 170: 1445-1453.
20. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17: 98-110.
21. Holtkamp N, Ziegenhagen N, Malzer E, Hartmann C, Giese A, von Deimling A. Characterization of the amplicon on chromosomal segment 4q12 in glioblastoma multiforme. Neuro Oncol 2007; 9: 291-297.
22. Kozak KR, Mahadevan A, Moody JS. Adult gliosarcoma: epidemiology, natural history, and factors associated with outcome. Neuro Oncol 2009; 11: 183-191.
23. Han SJ, Yang I, Tihan T, Prados MD, Parsa AT. Primary gliosarcoma: key clinical and pathologic distinctions from glioblastoma with implications as a unique oncologic entity. J Neurooncol 2010; 96: 313-320.
24. Mulholland PJ, Fiegler H, Mazzanti C, Gorman P, Sasieni P, Adams J et al. Genomic profiling identifies discrete deletions associated with translocations in glioblastoma multiforme. Cell Cycle 2006; 5: 783-791.
25. Shete S, Hosking FJ, Robertson LB, Dobbins SE, Sanson M, Malmer B et al. Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet 2009; 41: 899-904.
26. Snuderl M, Fazlollahi L, Le LP, Nitta M, Zhelyazkova BH, Davidson CJ et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 2011; 20: 810-817.
27. Little SE, Popov S, Jury A, Bax DA, Doey L, Al-Sarraj S et al. Receptor tyrosine kinase genes amplified in glioblastoma exhibit a mutual exclusivity in variable proportions reflective of individual tumor heterogeneity. Cancer Res 2012; 72: 1614-1620.
28. Szerlip NJ, Pedraza A, Chakravarty D, Azim M, McGuire J, Fang Y et al. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci USA 2012; 109: 3041-3046.
29. Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DW, Kaper F et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 2012; 4: 136ra68.
30. Nannya Y, Sanada M, Nakazaki K, Hosoya N, Wang L, Hangaishi A et al. A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res 2005; 65: 6071-6079.
31. Yamamoto G, Nannya Y, Kato M, Sanada M, Levine RL, Kawamata N et al. Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide- polymorphism genotyping microarrays. Am J Hum Genet 2007; 81: 114-126.